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Evolution of multiple cell clones over a 29-year
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Chronic lymphocytic leukaemia (CLL) is a frequent B-cell malignancy, characterized by
recurrent somatic chromosome alterations and a low level of point mutations. Here we
present single-nucleotide polymorphism microarray analyses of a single CLL patient over 29
years of observation and treatment, and transcriptome and whole-genome sequencing at
selected time points. We identify chromosome alterations 13q14 , 6q and 12qþ in early
cell clones, elimination of clonal populations following therapy, and subsequent appearance of
a clone containing trisomy 12 and chromosome 10 copy-neutral loss of heterogeneity that
marks a major population dominant at death. Serial single-cell RNA sequencing reveals an
expression pattern with high FOS, JUN and KLF4 at disease acceleration, which resolves
following therapy, but reoccurs following relapse and death. Transcriptome evolution
indicates complex changes in expression occur over time. In conclusion, CLL can evolve
gradually during indolent phases, and undergo rapid changes following therapy.
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C
hronic lymphocytic leukaemia (CLL) is the most common
B-cell malignancy in the US, Canada and Western Europe,
and remains an incurable disease1–5. Recurrent somatic
alterations include deletions of chromosomes 11q, 13q14
and 17p, and trisomy 12 (refs 6,7) and point mutations in
SF3B1, NOTCH1 and TP53 (refs 8–10). CLL represents an
interesting model to study cancer progression, therapy response
and relapse, as the disease is often detected many years before the
initiation of treatment, and patients survive for a considerable
time. We took advantage of an extremely rare situation of having
yearly viably frozen tumour cells from a patient over the past 18
years of her 29-year disease course. By performing single-
nucleotide polymorphism (SNP) array analysis at 16 yearly time
points,
as well as single-cell whole-genome sequence (WGS) and
transcriptome, we have a detailed picture of molecular changes
over time. During this time period, the patient had a 9-year
period of indolent disease, a marked rise in white blood cell
(WBC) counts, and multiple years of cytotoxic therapy with a
moderate disease progression, followed by more rapid
progression and chronic infections, and death. The resulting
analysis provides an unparalleled look at cancer evolution over
nearly 20 years.
Results
Patient description. A female CLL patient was diagnosed in 1972
at age 47, with no evidence for cytogenetic abnormalities.
We divide her disease into an early phase of observation
(no treatment of disease lasting until 17 years after diagnosis),
a middle phase (moderate disease progression requiring treat-
ment, 18–25 years) and a late phase (disease progression, chronic
infections and death, 26–29 years; Fig. 1b; Supplementary Fig. 1).
Cytotoxic therapy (chlorambucil, an alkylating agent) adminis-
tered in year 16, 22/23 resulted in a short-lived remission;
eventually the patient progressed and died of her disease 29 years
after diagnosis at age 76.
SNP microarray analysis. To assess the sequence of changes in
chromosomal abnormalities, we performed microarray analysis
on tumour cells at 16 time points over 21 years (Figs 1a and 2;
Supplementary Figs 2–6). There were no detectable aberrations at
year 8 or 27 that reﬂect early disease and remission stages,
respectively. Chromosome 6q and 13q deletions, copy-neutral
loss of heterogeneity (LOH) on 10p and gain on chromosome
12 (years 10–12, 14, 17, 19–26 and 28) with at least two different
events at each time point detected (Fig. 2; Supplementary Fig. 7).
Chromosome 13q was found for all 14 time points with
alterations. The focal deletion region 13q14.3 was identiﬁed at
early time points and persisted to the end (years 10–28) and
coincided with 6q and 12qþ alterations. The large 13q
deletion involving the RB1 gene (13q14.2) was found at later time
points (years 20–25; Fig. 2; Supplementary Fig. 7), and may reﬂect
disease progression and clonal selection. Chromosome 12 trisomy
was found at later time points (years 25–28) and coincides with
chromosome 10p copy number LOH (CNLOH; Fig. 2).
Whole-genome and single-cell sequencing. To better understand
the genomic changes, we sequenced the whole genome of
unsorted peripheral blood mononuclear cells (PBMCs) DNA
samples from years 10, 14, 21, 23, 24, 26 and 28 (Supplementary
Table 1). The copy number variation (CNV) patterns were highly
consistent with the results of the SNP microarray (Supplementary
Figs 8,9). Interestingly, 6q deletion is always present with the 12q
duplication (Fig. 3a). Copy-neutral LOH of chromosome 10p was
found for four later time points (years 25–28) accompanied by
whole chromosome 12 duplication (Fig. 3a). The disappearance
of 6q deletion and 12q duplication, and the appearance of 10p
CNLOH and 12 trisomy may reﬂect clonal selection in response
to treatment. A low number of apparent somatic mutations were
detected. These include S219C in MYD88 in 11–30% of reads in
years 21, 23, 24 and 26, but undetectable in years 10, 14 and 28;
and G49S in MED12 in 11% of reads only in year 26 (Supple-
mentary Table 2). Both of these mutations have been previously
detected in CLL10.
To characterize the chromosome abnormalities at the single-
cell level, low-coverage WGS from years 23 and 28 cells was
generated (Fig. 1a; Supplementary Fig. 2; Supplementary
Table 3)11,12. The data reveals clusters of tumour cells with
chromosome 13q , chromosome 6q and partial or complex
trisomy of chromosome 12 (Fig. 3b; Supplementary Fig. 10). The
CNVs of 6q , 12þ , trisomy 12, focal 13q and large 13q
detected by SNP microarray were all present in the single cells.
However, single-cell analysis allows the CNVs to be resolved into
ﬁve distinct sub-populations: normal-like; focal 13q only; focal
13q and large 13q ; 6q and 12qþ , 13q14.3 ; and
trisomy 12 only (Fig. 3b). The chromosome 12q gain at year
23 always co-occurred with the 6q deletion consistent with the
results of SNP microarray. These two CNVs were also
accompanied by the focal 13q deletion. The remaining cells
harboured either the large and focal 13q deletion or only the focal
13q deletion, for a total of three distinct cell populations. In year
28, the chromosome 12 trisomy emerged in the absence of other
CNVs, indicating a novel origination of this clone. By combining
the CNVs proﬁles from SNP array and single-cell sequencing, we
reconstructed that the focal 13q14.3 deletion appears ﬁrst,
followed by the co-occurring 6q and 12qþ events (Fig. 3a).
A new clone with the large 13q14.2-14.3 deletion is ﬁrst detected
in year 20. Subsequently, the patient had multiple infections and
elevated WBC counts, and after cytotoxic therapy (year 16, 22/23)
and splenectomy in year 25, all chromosomal abnormalities were
undetectable except the focal 13q13.3 deletion. In year 24, both
CNLOH of chromosome 10 and trisomy 12 emerge, both of
which persist until year 28.
Single-cell transcriptome analysis. To investigate gene expression
proﬁles over time, we performed single-cell RNA transcriptome
sequencing (RNA-seq)13 on 300 unsorted tumour cells from the
year of year 10, 20, 23, 26 and 28 (Supplementary Fig. 13;
Supplementary Table 4). Unsupervised hierarchical clustering and
principal component analysis (PCA) yielded six clusters (Fig. 4a;
Supplementary Fig. 14). Cells from the earliest time point (year 10)
are almost exclusively found in cluster D suggesting that this is the
earliest detectable proﬁle, and several cancer-related genes,
including MAPK4 (ref. 14), ERBB4 (ref. 15) and PDGFRA16 are
in this cluster (Fig. 4b; Supplementary Tables 5 and 6). In year 20,
the cells adopt almost exclusively cluster F that contains several
transcription factors involved in stem cell regulation, such as JUN,
FOS, KLF4, KLF6 and CDKN1A, the MYD88 cascade (FOS, JUN,
NFKBIA and RPS6KA5) or downstream signalling of the B-cell
receptor (BCR; REL, CDKN1A and NFKBIA)17,18 (Fig. 4b;
Supplementary Tables 5 and 6).
Beginning in year 23, the cells developed a greater diversity of
expression proﬁles divided into two major branches with clusters
A, B and C, predominant in post-treatment samples. The cells
from year 23 contain mostly proﬁles B and C; and in year 26,
when the patient was in remission the cells largely reverted to
cluster D. Finally, in year 28, at relapse, the cells again developed
a great diversity with 56% of the cells adopting expression
patterns clusters A and C, and 36% of cells a new expression
proﬁle, cluster E (Table 1; Fig. 4b; Supplementary Table 5).
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Therefore, the single-cell expression analysis reveals a diverse
evolution of expression proﬁles over time and during treatment,
remission and disease relapse.
To further explore evolutionary models based on the single-cell
RNA-seq data, we performed cell fate decision analyses using the
Monocle program19 to reorder the cells by their differential
expression genes proﬁles. This pseudo-temporal ordering analysis
decomposed the 300 cell proﬁles into three trajectories (Fig. 4c,d).
The ﬁrst trajectory is dominated by the oldest cells from year 10. The
second trajectory contains mostly cells from year 20 and the third
trajectory cells from year 23 followed by year 28 cells. The cells at the
end of the third trajectory are mostly the year 28 cells from cluster E.
The program Monocle groups genes with similar expression
patterns along the pseudo-temporal trajectories. Several of these
groups contain a high–low–high expression pattern, with high
expression in early stages of leukaemia development, low expression
after therapy and remission, and high upon relapse (Supplementary
Fig. 15; Supplementary Table 7). These clusters are enriched in
cancer-related pathways, such as BCR signalling, epidermal growth
factor receptor (EGFR) signalling and extracellular signal-regulated
kinase (ERK) signalling. Another group (group 7) is highly
signiﬁcantly enriched in cell cycle-related cyclin A and E genes,
and NF-KappaB genes involved in B-cell development. This group
displays low expression during the initial stages of leukaemogenesis
and the highest expression at the early portion of trajectory 3.
Discussion
In summary, we have performed multiple microarray, bulk and
single-cell DNA and RNA analyses across the evolutionary
lifespan of a single CLL patients’ disease, response to therapy,
relapse and death. We can divide the disease process into three
phases:
In the early phase, at the ﬁrst time point, year 10 after clinical
presentation of CLL, a focal deletion of chromosome 13q14.3 was
present along with a deletion of a portion of chromosome 6 and a
gain of chromosome 12q. Single-cell analysis showed that the
6q and 12qþ alterations are present in the same cells, which
lack the chromosome 13 deletion (Fig. 5). This is consistent with
data that 13q cells can occur many years before CLL diagnosis
(manuscript in preparation). The mosaic fraction of the 6q and
12qþ alterations change in parallel over the period from year
10–19, consistent with the cell population containing these
variants varying over time.
In the middle phase, in year 20, the chr13 deletion expanded to
include the RB1 gene, an event associated with poorer
prognosis20, and a mutation in MYD88 (S219C) is also
detected. These events are accompanied by a marked alteration
in the gene expression pattern to expression cluster F. Elevated
expression of FOS and JUN transcription factors and oncogenes,
KLF4 (refs 21,22), one of the critical stem cell induction genes, as
well as REL23, CDKN1A24 and B-cell oncogenes are observed.
This corresponds to the peak of a marked rise in WBC counts
with the expansion of the chr13 deletion to include RB1 may lead
to the altered regulation of one or more transcription factors,
such as FOS/JUN and KLF4 accelerating the growth of the
leukaemic cells.
In the late phase, in year 22, further cytotoxic therapy was
administered and in year 23 the expression pattern changed to
one of high diversity with multiple different expression clusters
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Figure 1 | Sample and clinical information. (a) Schema of the sample isolation and the sequencing strategy. FACS, ﬂuorescence-activated cell sorting.
WGS, whole-genome sequencing. RNA-seq, RNA sequencing. (b) Clinical information and corresponding samples analysed. Top, white blood cell counts
(WBC) from diagnosis to year 29 following diagnosis. The dashed grey line indicates the normal upper level of WBC. Additional clinical information is
shown in Supplementary Fig. 1. Bottom, the matched sequencing samples.
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present in different cell populations. Furthermore, in year 24 we
see the appearance for the ﬁrst time of a CNLOH event on chr10
and a complete trisomy of chr12, consistent with these events
being concurrent in the same population. The single-cell
sequencing shows that the trisomy 12 event occurred on an
otherwise normal chromosome background.
The patient required a splenectomy year 25, and in year 26 the
gene expression pattern reverts to cluster D, the expression
pattern present in the indolent phase. In year 27, most of the
chromosome abnormalities become undetectable, and the
patients’ disease was stable. However, this state is short lived,
and in year 28 all the chromosome abnormalities present before
remission are detectable again. The patient suffered from
increasing and recurrent respiratory tract infections and died in
year 29. The gene expression pattern in year 28 shows a similar
diversity in gene expression clusters as in 23, but the proportion
of cells in each cluster has changed markedly. Therefore, we can
follow the progression of the patients’ disease at the molecular
level along with the clinical changes or remission and relapse.
To further understand the alterations in gene expression over
time we used a new method, Monocle19, to analyse temporal
changes in gene expression. Because cells do not synchronously
move through expression states, this analysis can be used to reorder
the cells based on both the time and expression state identifying
genes that are coordinately expressed. This analysis showed cells
from trajectory 1 contain many of the cells of year 10 and early time
points. One group of cells branches off and stops (trajectory 2), and
we interpret this as being cells eliminated by the therapy. Nearly, all
the year 26 (cluster D) cells are in here. The third trajectory is
composed mostly of cells with complex expression proﬁles from
years 23 and 28. The ﬁnal group of cells is almost exclusively from
the year 28 time point and expression cluster E. Cluster E is a very
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Figure 2 | Representative CNV proﬁles detected by SNP microarray. (a) The CNV proﬁles of 16 time points during the years 8–28 from diagnosis are
shown. (b) The SNP array plots of 13q in years 10 and 20 are shown.
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minor component (2–7%) of the cells in year 10–26, but is 36% of
the cells in the year 28. This suggests that these cells were rapidly
proliferating at the end stage of disease. The cell population that
contains the trisomy 12 and most likely the CNLOH event on
chromosome 10, are likely the cluster E-expressing cells, containing
FGF5, LYN, SETD2 and IL17RD. LYN25 is a tyrosine kinase that is
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Figure 3 | CNV proﬁles detected by WGS and single-cell WGS. (a) The timeline of CNVs detected by combined SNP microarray and WGS. CNLOH,
copy-neutral loss of heterogeneity. (b) The CNV proﬁles of 6q, 12 and 13q14 by single-cell WGS. Two cells were removed (Supplementary Figs 11 and 12).
(c) The CNV proﬁles of the 13q14 region. The cells with a normal karyotype in this region were removed. The CNV proﬁles of all cells were showed in
Supplementary Fig. 10b.
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13765 ARTICLE
NATURE COMMUNICATIONS | 7:13765 | DOI: 10.1038/ncomms13765 | www.nature.com/naturecommunications 5
expressed in B cells and mediates response from the BCR. LYN is
located on chromosome 12, and the trisomy 12 event may
contribute to this overexpression.
Deletions of chromosome 13 are the single most common
somatic events in CLL. The focal 13q14.3 deletion contains two
long-non-coding RNA genes DLEU1 and DLEU2 and is thought
to disrupt the expression of miR-16-1 and miR-15a (ref. 26).
This deletion is a good prognosis factor for CLL patients.
However, large deletions that also contain RB1 are poor
prognostic factors, especially when homozygous. While it has
been assumed that the focal deletions expand to become the
larger deletions, our data (Fig. 3c) provide direct evidence for this,
as we can see individual single cells with transition states from the
focal to expanded deletion. Interestingly, homozygous large
deletion cells are almost completely absent from the single cells
in year 28, indicating that they were eliminated by the therapy.
The study is limited by involving a single patient, and therefore
the conclusions to be drawn to other CLL subjects would require
other analyses. However, this patient does have most of the
commonly occurring chromosomal aberration found in CLL and
therefore is a typical case in that respect. Our array and single-cell
analyses over so many time points allows the reconstruction
of the distribution and evolution of these chromosome abnorm-
alities during the disease process. This patient had an indolent
course of disease for many years, but once the disease required
therapy, clinical progression proceeded in a typical manner.
The most unique ﬁndings are the dramatic changes in gene
expression patterns seen in single cells over time. Again it
remains to be seen if this is typical of CLL from future single-cell
multiyear analyses.
In conclusion, we have performed, to our knowledge, the most
detailed and extensive analysis of a single leukaemia patient in
terms of number of samples analysed over time, using multiple
DNA and RNA sequencing methods on bulk and single cells.
We provide molecular analyses of the indolent disease state, acute
disease, response to therapy and remission, and ﬁnally relapse.
Table 1 | Percentage of single cells in each expression cluster by date.
Cluster Year 10 (%) Year 20 (%) Year 23 (%) Year 26 (%) Year 28 (%)
A 0 0 11 3.7 36
B 3.2 0 41 0 8.7
C 6.5 4.2 30 7.4 20
D 77 0 11 82 0
E 3.2 2.2 6.5 3.7 36
F 9.7 94 0 3.7 0
The percentage of single cells in each expression cluster as determined in Fig. 4a is shown at each time point tested. Bolded values are the highest at that date.
80 12 14 16 18 20 22 24 26 2810
6q–
Focal 13q-
12q+
Large 13q–
10 CNLOH
Trisomy 12
Cytoxic treatment
(chlorambucil)
and prednisone
Splenic
embolization
and Splenetomy
Diagnosis Died
D F
B
C
D
A
E
Cluster
B
C
D
E
F
A
Timeline
CNVs
Expressions
PDGFRA
ERBB4
MAPK4
JUN
FOS
KLF4
MAP3K8
ID3
KLF6
JUND
H3F3A TCL1A
MAP3K12
HOXB7
LYN
SOX13
FGF5
PDGFRA
ERBB4
MAPK4
Cytoxic treatment
(chlorambucil)
and prednisone
Figure 5 | The inferred tumour evolution path of the CLL patient. The upper panel represents the timeline of the main treatments. The middle panel
represents the inferred CNVs evolution model and the lower panel represents the percentage of cells from different clusters at expression level.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13765
6 NATURE COMMUNICATIONS | 7:13765 | DOI: 10.1038/ncomms13765 | www.nature.com/naturecommunications
Because the progression of CLL is in generally slow compared
with other leukaemias and solid tumours, these disease stages can
be dissected and provide insights into tumour progression and
evolution. While our study has the limitation of following a single
patient, we believe the insights are valuable to understanding
cancer.
Methods
Patient information. The subject was diagnosed with CLL after a 1972
medical visit, when she presented with persistent upper respiratory infections
(WBC¼ 9,700; 47% lymphocytes). She received antibiotics and improved, but
small posterior cervical and axillary nodes, and absent splenomegaly were noted
on physical exam. Eventually, she received a referral to a haematologist who
performed a sternal aspiration that revealed increased lymphocytes and a picture
compatible with CLL. No therapy was required. At the time of her diagnosis,
two brothers and her father also had a family history of CLL. Her WBC in 1973
ranged between 15–18,000 with 80% lymphocytes, and Hgb value of 13 g dl 1
and platelets 250–300,000 cells per ml. Physical exam at that time showed no or
minimal lymphadenopathy and no splenomegaly. Two years after diagnosis a
bone marrow biopsy revealed mature lymphocytes with ‘focal lymphoid aggregates’
consistent with at diagnosis of CLL or well-differentiated lymphocytic lymphoma.
Between 2 and 6 years after diagnosis she was followed with the only physical
ﬁnding noted being a very small (o1 cm) right axillary lymph node. By year 8,
her WBC had risen to 35,000 cells per ml, but she remained asymptomatic without
additional physical ﬁndings. By year 13, mild splenomegaly was noted, with small
lymph nodes persisting (anterior and posterior cervical, and right axilla). In year
16, with WBC¼ 53,200 cells per ml, Hgb 11.2 g dl 1 and platelets 114,000 cells
per ml she received a short course of chlorambucil and prednisone. Her white
count went from 56,000 to 25,000 cells per ml in year 17; platelets and Hgb
remained stable B100,000 cells per ml and 11.0 g dl 1, respectively. Her spleen
continued to slowly increase in size during this period and by late year 17 her
counts had returned to earlier levels, WBC¼ 53.2 cells per ml, Hgb¼ 12.5 g dl 1,
platelets¼ 122,000 cells per ml and the spleen was measured 16 cm below the left
costal margin. Otherwise, she continued to feel well with normal everyday activ-
ities. In year 19 following diagnosis she was involved in a serious car accident and
suffered a splenic haematoma and other fractures (ankle and sternum). An ultra-
sound exam at that time revealed a 19 cm spleen. Her acute injuries and the
haematoma resolved. Between year 22 and 23, she underwent another further
treatment with chlorambucil and prednisone. This did not markedly change
either her spleen size or WBC. By year 24, her WBC had risen to 80,000 cells per ml,
Hgb 9 g dl 1 and platelets 70,000 cells per ml. It was felt that her very large
spleen was increasingly compromising her clinically, so on year 25 she underwent
splenic embolization that was unsuccessful, followed by a splenectomy. The
pathologic diagnosis of the spleen was ‘splenomegalic CLL’ and it measured
(38.5 24.7 12.3 cm). She recovered and her WBC stabilized. Increasingly,
she suffered from sinus and pulmonary infections, treated with rotating courses
of antibiotics (levoquin, augmentin and cephlin) and monthly intravenous IG.
In year 27, a breast biopsy was performed for a right breast mass and it revealed
‘lymphocytes’ consistent with CLL. WBC¼ 38,300 cells per ml, Hgb¼ 13 g dl 1
and platelets¼ 221,000 cells per ml. In year 28, increasing pulmonary infections and
bronchiectasis were noted. Lymph nodes were unchanged. WBC¼ 43,300 cells per
ml, Hgb¼ 13.3 g dl 1 and platelets¼ 210,000 cells per ml. The subject died in year
29, following diagnosis of increasing infectious complication of CLL. The studies
were approved by the institutional review board of NIH, and informed consent was
obtained from this subject.
Cell staining for four-colour ﬂow cytometry. The PBMCs from the CLL patient
were stained using conjugated four-colour anti-human antibodies (ﬂuorescein
isothiocyanate, FITC-CD5; phycoerythrin, PE-CD3; allophycocyanin, APC-CD19
and peridininchlorophyll-protein cyanine 5.5, PerCP-CD45) in a single tube.
Brieﬂy, the PBMC cells were thawed in a 37 C water bath, the cells washed twice
using cold Flow Cytometry Staining Buffer Solution (eBioscience), centrifuged at
3.3g for 1min, re-suspended in 100 ml of staining buffer solution and transferred to
5ml tubes (Falcon). After addition of 5 ml of each antibody to 100ml of cells, the
cells were incubated at 4 C in the dark for 40min, centrifuged and re-suspended in
0.5ml of staining buffer solution and kept on ice until sorting. Controls included
(1) cells only; (2) CD3 (PE); (3) CD5 (FITC); (4) CD19 (APC); and (5) CD45
(PerCP-Cy5.5). All antibodies were obtained from eBioscience.
The different target populations included (1) tumour B cells with
CD19þ /CD5þ (population 7, P7); (2) normal T cells with CD3þ /CD5þ
(population 5, P5); and (3) normal B cells with CD19þ /CD5 (population 8, P8;
Supplementary Fig. 2). Cells were sorted on a Becton Dickenson FACSAria II with
FACSDiva v6.1 software. The cell sorter was run with a 3,050mW 488 nm solid
state laser and a 40mW 640 nm solid state laser. The detectors for FSC, SSC had
488/10 band-pass ﬁlters. These optical ﬁlters were used in front of the ﬂuorescent
detectors: 530/30 bp (FITC), 575/25 bp (PE), 710/50 bp (PerCP-Cy5.5) and 670/30
(APC). Compensations were calculated through the auto-compensation matrix
using single-stained samples. The cells were sorted using a 70-mm nozzle run at a
sample ﬂow rate of 6,000–10,000 cells per second on a sort precision of 8-32-0.
Both sample and collection tubes were maintained at 4 C during the sort. Single
cells were sorted into 96-well plates with the Automated Cell Deposition Unit run
at a sample ﬂow rate of 200–400 cells per second at a sort precision of ‘single cell’
(0-32-16). Only the sample was maintained at 4 C during the 96-well plate sorts.
Bulk-sorted cells were viably frozen in freeze medium in a programmable cell
freezer and stored in liquid nitrogen until single-cell selection was performed.
In most cases, we were able to collect more than one million tumour B cells,
but normal T and normal B were obtained in only small quantities.
Sorted cell DNA extraction. Extraction of DNA from sub-populations of cells
was performed using the ZR-Duet DNA/RNA MiniPrep kit (ZYMO Research).
The sample which contained normal T cells from year 10 and 28 was removed
from analysis due to low quality.
Single-cell RNA sequencing. All complementary DNA products of single CLL
B cells in this study were prepared by a microwell based a platform called MIR-
ALCS13. A total of 1 ng complementary DNA product from each cell was used
for library construction using the TruePrepTM Mini DNA Sample Prep Kit
(Vazyme Biotech) followed by barcode labelling. A total of 362 single cells were
sequenced on Illumina Hiseq 2000 sequencing system with SE50 sequencing
strategy (Supplementary Table 4). Of these cells, 38 cells were from year 10, 48
cells from year 20, 126 cells from year 23, 35 cells from year 26 and 115 cells
from year 28.
Single-cell DNA sequencing. Single CLL tumour cells are selected by a
Micromanipulator (Eppendorf TransferMan NK2) under the inverted ﬂuorescence
microscope (Olympus IX-71), and pipetted into PCR tubes that contained 2 ml
lysis buffer. Single-cell DNA ampliﬁcation was carried out using the REPLI-g
Single Cell Kit (Qiagen), and ampliﬁed DNA with positive results for at least six out
of eight house-keeping genes were selected for subsequent library construction.
DNA was fragmented with the Covaris E-210 ultrasonicator with adjusted shearing
parameters. We puriﬁed the DNA fragments, blunted the ends, added A tails
and ligated them with adaptors to prepare Hiseq libraries. A total of 116 single cells
were sequenced on Illumina Hiseq 2000 sequencing system with PE 100 sequen-
cing strategy (Supplementary Table 3). Of these cells, 54 cells were from year
23 and 62 cells were from year 28.
Bulk DNA sequencing. DNA extracted from sorted cell population of year 10, 14,
21, 23, 24, 26 and 28 by using DNeasy Blood & Tissue Kit (Qiagen). We used
Covaris LE220 (Covaris) to break the genome DNA into fragments with a 350 bp
peak by optimal shearing parameters. We puriﬁed the fragments by using
Agencourt AMPure XP beads (Beckman Coulter). We repaired the ends of
fragments, added A tails and ligated the adaptors. After fragment size selection by
gel, we did 10 cycles of PCR to enrich the fragments. After puriﬁcation by
Agencourt AMPure XP beads (Beckman Coulter), we did the quality control of
libraries by Agilent 2100 Bioanalyzer (Agilent Technologies) and quantitative PCR
using ABI StepOne Plus Real-Time PCR system (Life Technologies). Paired-end
150 bp length reads were sequenced on Illumina Hiseq 4000 sequencing system.
SNP array methods. Genomic DNA was extracted from unsorted bulk cell DNA,
as well as sorted tumour B cells, and normal T and B cells. Genomic DNA was
screened and analysed at the NCI according to the standard sample handling
process of the Cancer Genomics Research Laboratory, Division of Cancer Epide-
miology and Genetics before genotyped using Illumina Inﬁnium OmniExpress
BeadArray assays. Sample intensity ﬁles (two ﬁles per sample, for red and green
channels) were loaded into the Illumina GenomeStudio software. The intensity
data were normalized using the Illumina ﬁve-step self-normalization procedure,
which used information contained in the array itself to convert raw X and Y
(allele A and allele B) signal intensities to normalized values. The chromosome
mosaicism was detected using log R ratio (LRR) and B allele frequency (BAF).
The LRR value is the normalized measure of total signal intensity and provides data
on relative copy number. The BAF derived from the ratio of allelic probe intensity
is the proportion of hybridized sample that carries the B allele as designated by the
Illumina Inﬁnium Assay. The LRR and BAF values for each assay were exported
from GenomeStudio software using the ‘Genotype Final Report’ format.
Quantile normalization was applied to remove dye bias and improves the
asymmetry in the detection of the two alleles for each SNP, which inﬂuences
both allelic proportions and copy number estimates. GC/CPG correction was
applied to reduce the wavy patterns of signal intensities and improves the accuracy
of CNV detection. The LRR and BAF were re-estimated on the quantile-
normalized and GC/CpG corrected values. All of these procedures were
implemented using GLU software package (http://code.google.com/p/glu-genetics/)
that was developed at Cancer Genomics Research Laboratory. The renormalized
LRR and BAF values from qualifying assay were then analysed using
custom software pipelines that involved BAF segmentation packages
(http://baseplugins.thep.lu.se/wiki/se.lu.onk.BAFsegmentation) to detect mosaic
copy number aberration with minimum of 20 probes per segment to minimize
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the false discovery. The copy number status was assigned (mosaic loss, mosaic gain
and mosaic copy-neutral LOH) and mosaic proportion of abnormal cells was
estimated. All potential events were plotted. False positive calls were excluded from
analysis base on manual review on each plot.
To prevent the lack of detection of the chromosome 13q14.3 focal deletion,
due to the small size of this region, a t-test (two sided) was used to target the region
between bases 49,139,793 and 50,269,706 (GRCh36). The LRR and BAF were
examined for deviations from expected LRR and BAF. For each time point, an
unequal variance t-test was applied to ﬁnd mean LRR value and mean BAF for the
tested region that is signiﬁcantly different from mean LRR values and mean BAF
on chromosome 1 (used as the reference). Results from t-test were plotted and
manually reviewed to conﬁrm a 13q14.3 focal deletion.
Public data set access. The human (Homo sapiens) reference genome sequence
(Hg19, GRCh37) was downloaded from the University of California Santa Cruz
Genome Bioinformatics (http://genome.ucsc.edu/). The transcriptome reference
annotation GTF ﬁle27 was downloaded from http://www.ensembl.org/. The GTF
ﬁle retained the information of autosomes and sex chromosome X before further
analysis. The known SNPs and indels in 1000 Genomes Project and dbSNP v137
(ref. 28) were downloaded from ftp://ftp.broadinstitute.org/.
Genome alignment variant calling. Reads resulting from Illumina Hiseq 4000
sequencing were aligned to hg19 (UCSC) using BWA (v0.7.12-r1044)29 with
parameters ‘mem –t 8 P –M’ and the generated ﬁles were then sorted and
PCR duplicates removed using Picard (v1.72) (http://broadinstitute.github.io/
picard). Bamtools (v2.1.1)30 was used to ﬁlter out multi-mapped reads and those
with mapping quality o1. Subsequently, the BAM ﬁles were indexed by samtools
(v0.1.18)31.
SNPs and indels calling. We detected SNPs and indels according to the GATK32
best practice workﬂows. After duplicate-read removal using Picard, the BAM ﬁles
were recalibrated and variants were called using GATK v3.3.0 with known indels
in the 1000 Genomes Project33 and known SNPs in dbSNP v137 (ref. 28). Then we
built the index of each VCF ﬁle, compressed them using tabix (v0.2.6)34 and
merged all SNPs in the VCF ﬁles using VCFtools (v0.1.12b)35. The SNPs were
ﬁltered using GATK with parameters ‘-T VariantFiltration --ﬁlterExpression
‘QDo2.0 || FS460.0 || MQo40.0’ --ﬁlterName ‘snp_ﬁlter’ --clusterSize 2 --
clusterWindowSize 10’.
Minor allele frequency analysis. Because there is no normal sample to use as a
control, we could not detect the precise SNVs of the tumour samples. Therefore,
we tried to eliminate possible germline SNPs and analysed the minor allele
frequency changes from year 10–28. We annotated all SNPs using ANNOVAR36
with parameters ‘-protocol refGene, popfreq_all_20150413, snp138NonFlagged –
operation g,f,f’. The SNPs with allele frequency40.0001 in 1000G_AMR and
ExAC_AMR data sets and the SNPs marked as snp138NonFlagged were removed
from further analysis. To obtain a more conﬁdent SNP allele frequency, we retained
only those SNPs with depth Z30 in all seven samples. A total of 6,149 SNPs were
retained. We then performed the PCA analysis using the R package FactoMineR37,
and ﬁltered out the sites with PC14 1 (Supplementary Fig. 16a,b), which showed
no signiﬁcant difference among each other and were thought to be possible
germline SNPs.
The remained 1,065 SNPs were clustered using SOTA in R package clValid38
and divided into 12 groups. Of the 12 clusters, 3 clusters were removed because the
minor allele frequency (MAF) changed in a small range among all samples and
were considered as possible germline SNPs (Supplementary Fig. 16c). Most of these
SNVs are in introns and non-coding regions and are not likely to affect cancer
progression. By clustering the SNVs with similar MAF pattern, we found SNVs
(cluster 4) that are lost in later time points and may represent regions of deletion
(Supplementary Fig. 17). Other SNVs increased in frequency and then disappeared
perhaps represent variants in cells eliminated during treatment. Some SNVs
showed increasing MAF during the later stages and may represent accumulated
passenger mutations.
SV detection in bulk samples. After duplicate-read removal using Picard,
structural variations were detected for each sample separately using CREST39 with
Hg19 as the reference genome. Then, the generated tumour.predSV.txt ﬁles were
annotated using ANNOVAR with Hg19 and dbSNP v137. For an alternative
method to call CNVs, we removed deletions and ampliﬁcations from the results
of CREST. SVs with supporting readso3 in each sample were ﬁltered out. But we
did not detect any high conﬁdence rearrangements of known cancer genes
(Supplementary Table 8).
Genome alignment of bulk and single-cell samples for CNV calling. Reads
resulting from Hiseq 2000 sequencing were aligned to Hg19 (UCSC) using
Bowtie (v1.0.0)40 with parameters ‘-S -t -m 1 --best –strata’. Then we transformed
the subsequent SAM ﬁles to BAM format and sorted them using samtools
(v0.1.19). Afterwards, we also used samtools (v0.1.19) to remove PCR duplicates
and build an index for each BAM ﬁle.
CNVs calling in bulk and single-cell samples. Copy number was computed for
each sample separately using a modiﬁed method based on that developed by the
Cold Spring Harbour Laboratory41,42. We followed their bioinformatic workﬂow to
detect CNVs and used the Python script provided to generate the ‘bin boundaries’
ﬁle for 10,000 bins in Hg19 suitable for 150-bp length reads. For single-cell
samples, the ‘bin boundaries’ ﬁle had 10,000 bins and was suitable for 100-bp
length reads. We calculated the read number and the ratios based on the average
read number in each bin of all bulk and single-cell samples. After GC correction,
the R package DNAcopy43 was used to calculate the copy number ratios and merge
bins into segments. Bins in the same segment had the same segment ratio and
segment ratios equal to 1 represent normal. The ratios41 represent ampliﬁcation,
and the rations o 1 represent deletion. The GC corrected ratios of each bin
and the inferred rations of segments of speciﬁc chromosomes were extracted to
display the detailed copy number changes for bulk and single-cell samples
(Supplementary Figs 9,11,12).
Single-cell WGS ﬁltering and clustering. The Median Absolute Pairwise
Difference (MAPD)44 measures the absolute difference between the log2 copy
number ratios of every pair of neighbouring bins and then takes the median
across all bins. Higher MAPD scores reﬂect greater noise, typically associated with
poor-quality samples. After obtaining the copy number of each bin for all single-
cell-genome sequencing samples, we adopted the MAPD algorithm to ﬁlter out
14 samples with MAPD Z1.4. Then, we transformed the segment ratios of the
remained cells into a log2-scale, and set the log2-scaled ratios with values41 or
o 1 to 1 or  1, respectively. The transformed segment ratios were used to
the hierarchical clustering analysis using R package NMF45 with the clustering
method of ‘ward.D2’.
False positives in single-cell CNV proﬁles. When we clustered the single cells
using the CNVs, we found two cells with 6q deletions that had a larger ampliﬁcation
in chr12 than other cells (Fig. 3b). We extracted the raw ratios of each bin before the
segment ratio calling, and found the ratios showed signiﬁcant difference between the
different portions in the chr12 ampliﬁcation region in the same cells (Student’s t-test,
two sided, Supplementary Fig. 12). Although the differences of raw ratios between
the true ampliﬁcation region and the false positive region were signiﬁcant, we
speculated that the difference were not signiﬁcant enough for the CNV detection
methods. Therefore, the method merged the adjacent bins to the actual ampliﬁcation
region to generate a larger CNV, leading to a false positive result.
We also found two abnormal cells when we clustering the cells with the three
main CNV regions (chr6, chr12 and chr13). We extracted the CNV proﬁles of
the whole chromosomes, and found that both of these two cells harboured larger
CNVs. One cell harboured deletion of all chr6 and 13 and is trisomy 12
(Supplementary Fig. 11a–d) and the other cell, chr6 and 13 deletion and normal
chr12 (Supplementary Fig. 11e–h). We removed these two cells from the
hierarchical clustering analysis of the three speciﬁc CNVs shown in Fig. 3b.
Single-cell RNA-seq data processing. Reads resulting from Hiseq 2000 sequen-
cing were ﬁltered using an in-house Cþ þ script, and aligned using TotHat2 (ref.
46). The fragments per kilobase of exon per million fragments mapped (FPKM)
values were calculated using the R package edgeR47. The detailed process and
parameters were described in a recent publication13. The single cells with less than
one million reads mapping to gene regions were removed from further analysis.
Filtering of genes and samples. Cells with expressed genes (FPKM41) 48,000
were also ﬁltered out, as they showed much higher expression levels than the
average and likely contain more than one cell. To reduce the potential inﬂuence
of RNA degradation, we only retained the protein-coding genes. We then picked
a set of genes that were expressed in at least half of all cells with FPKM41 and
calculated the expressed gene number of every cell. We excluded from the analysis
any cells that expressed below the 10th percentile of that gene set and whose mean
FPKMr1. We also removed genes with the mean FPKM more than the 99th
percentile for all genes. In total, 300 single cells and 9,258 genes remained for
further analysis out of 362 total cells sequenced.
PCA and hierarchical clustering analysis. We used an in-house R script to
perform the PCA and hierarchical clustering. The PCA analysis was performed
on all the cells and genes after ﬁltering using the R package FactoMineR37. A total
of 80 genes, the ﬁrst 20 genes of the ﬁrst four principle components, were used
to perform the hierarchical clustering. The cells were divided into six groups
according to the result of the hierarchical clustering. We then performed the
Kruskal–Wallis rank sum test (KW test) and adjusted the P values using ‘fdr’
method. We retained the genes with q valueo0.01. The remaining genes were used
to perform the PCA, hierarchical clustering analysis and KW test. Genes with q
valueo0.01 were used for the third PCA and hierarchical clustering analysis, which
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were the ﬁnal results used in the paper (Fig. 4a). The cells were then divided into
six groups (A–F cluster) according to the hierarchical clustering, and we used the
hypergeometric distribution test to identify the marker genes. The P values
were adjusted using the ‘BH’ method, and genes with q valueso0.01 were
considered as particularly highly expressed marker genes in the A–F clusters
(Supplementary Table 5). We did not detect signiﬁcantly expressed genes in
cluster C.
Pseudo-temporal analysis. To further investigate the gene expression changes
during tumour evolution and the relationships between different cells from
different time points, we performed pseudo-temporal analysis using the R package
Monocle19. We ﬁrst detected the differentially expressed genes according to
corresponding time point of each cell using Monocle and 3,546 genes with a
Po0.01 were retained for further analysis. The pseudo-temporal path number
was set at 2, and the cells were divided into three trajectories. Considering that the
cells were not in a strict developmental state and that the intervals between
different time points were very long, we modiﬁed the pseudo-temporal ordering
of each cell. Cells were divided in to three groups according to the inferred pseudo-
temporal phases, and the relative orderings of cells in the same group remained
unchanged. The group containing the most cells from the earliest time (year 10)
was set to be the start of the pseudo-temporal path, and the group containing the
most cells from year 23 and 28 was set as the end of the path (Fig. 4c,d). The last
group was placed between the two groups. We then clustered the genes into
10 groups to make sure that the gene expression along the inferred pseudo-
temporal path reﬂected the changes along the actual time (Supplementary Fig. 15).
Therefore, we could combine the pseudo-temporal ordering and the actual time
to investigate the gene expression changes and their potential inﬂuences. Reactome
enrichment was performed on the genes from each group using the R package
ReactomePA48 with the 9,258 genes as the background and a q value cutoff of
0.05 (Supplementary Table 7). We did not detect enriched pathways in cluster 6.
Data availability. Raw data have been uploaded to the database of Genotypes and
Phenotypes (dbGAP, http://www.ncbi.nlm.nih.gov/gap/) under the study accession
code phs001177, SRA399097. This study includes all sequencing data from WGS
and whole-transcriptome sequencing. The remaining data supporting the ﬁnding
of this study are contained within the article and the Supplementary Information
ﬁles, or available from the authors on request.
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